Inventor

Barbora MALECOVA

Inventor

US

Overview

2022–2026

Patent span

Chemistry

Primary field (CPC C)

Patents· 24 as inventor

Public. Assignee & technology derived from the patent record. Each patent links to its LexDana page.

A61Kprimary

A61KPreparations for medical, dental or toiletry purposes22%

A61PSpecific therapeutic activity of chemical compounds or medicinal preparations22%

C07KPeptides22%

C12NMicroorganisms or enzymes22%

C12YEnzymes8%

C07DHeterocyclic compounds2%

C07FAcyclic, carbocyclic or heterocyclic compounds containing elements other than carbon, hydrogen, halogen, oxygen, nitrogen, sulfur, selenium or tellurium2%

C07HSugars2%

PatentTitleYear

12,529,056Compositions and methods of treating facioscapulohumeral muscular dystrophy2026 12,486,328Compositions and methods of treating facioscapulohumeral muscular dystrophy2025 12,427,202Compositions and methods of treating muscle dystrophy2025 12,364,769Nucleic acid-polypeptide compositions and uses thereof2025 12,263,224Compositions and methods of treating muscle atrophy and myotonic dystrophy2025 12,157,774Compositions and methods of treating facioscapulohumeral muscular dystrophy2024 12,104,156Compositions and methods of treating facioscapulohumeral muscular dystrophy2024 12,071,485Compositions and methods of treating facioscapulohumeral muscular dystrophy2024 12,049,629Compositions and methods of treating Facioscapulohumeral muscular dystrophy2024 11,999,955Compositions and methods of treating facioscapulohumeral muscular dystrophy2024 11,912,779Compositions and methods of treating facioscapulohumeral muscular dystrophy2024 11,872,287Compositions and methods of treating muscle atrophy and myotonic dystrophy2024 11,712,478Compositions and methods of treating muscle atrophy and myotonic dystrophy2023 11,707,532Compositions and methods of treating muscle dystrophy2023 11,583,591Compositions and methods of treating muscle atrophy and myotonic dystrophy2023 11,576,980Compositions and methods of treating muscle atrophy and myotonic dystrophy2023 11,554,176Compositions and methods of treating muscle atrophy and myotonic dystrophy2023 11,555,190Compositions and methods of treating Facioscapulohumeral muscular dystrophy2023 11,525,137Compositions and methods of treating Facioscapulohumeral muscular dystrophy2022 11,497,814Compositions and methods of treating muscle atrophy and myotonic dystrophy2022 11,446,387Compositions and methods of treating muscle dystrophy2022 11,364,302Nucleic acid-polypeptide compositions and uses thereof2022 11,253,607Compositions and methods of treating muscle atrophy and myotonic dystrophy2022 11,246,941Compositions and methods of treating muscle atrophy and myotonic dystrophy2022

Career & activity timeline

Assembled from patent assignee/location history and declaration credentials.

2022–2026Patents assigned to AVIDITY BIOSCIENCES INC (24)· patent assignee history

2022–2026Based in US· patent location history

2023Patents assigned to AVIDITY BIOSCIENCES LLC (1)· patent assignee history

Inventor activity

Assignee and location history derived from the patent record.

Assignees

Assignee	Patents	Span
AVIDITY BIOSCIENCES INC	24	2022–2026
AVIDITY BIOSCIENCES LLC	1	2023

Locations

Location	Patents	Span
US	24	2022–2026